Haematologica (Sep 2022)
Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study
- Michael Launspach,
- Dennis Temel,
- Emily Ohlendorf,
- Felix Zirngibl,
- Bianca Materne,
- Lena Oevermann,
- Hedwig E. Deubzer,
- Anton G. Henssen,
- Annette Künkele,
- Patrick Hundsdörfer,
- Horst von Bernuth,
- Axel Pruß,
- Angelika Eggert,
- Arend von Stackelberg,
- Peter Lang,
- Johannes H. Schulte
Affiliations
- Michael Launspach
- Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg
- Dennis Temel
- Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin
- Emily Ohlendorf
- Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin
- Felix Zirngibl
- Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin
- Bianca Materne
- Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Berlin
- Lena Oevermann
- Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin
- Hedwig E. Deubzer
- Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg
- Anton G. Henssen
- Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg, Germany; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Berlin
- Annette Künkele
- Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg
- Patrick Hundsdörfer
- Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Department of Pediatrics, Helios Klinikum Berlin-Buch, Berlin
- Horst von Bernuth
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; Deparment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany; Labor Berlin - Charité Vivantes GmbH, Department of Immunology, Berlin, Germany; Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, Berlin
- Axel Pruß
- Institute of Transfusion Medicine, Charité - Universitätsmedizin Berlin, Berlin
- Angelika Eggert
- Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg
- Arend von Stackelberg
- Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin
- Peter Lang
- Department of Hematology/Oncology and General Pediatrics, Children’s University Hospital, University of Tuebingen, Tuebingen
- Johannes H. Schulte
- Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg
- DOI
- https://doi.org/10.3324/haematol.2022.281134
- Journal volume & issue
-
Vol. 108,
no. 1
Abstract
No abstracts available.